[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633191":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":50,"collaborators":20,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":20,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":20,"maxAge":62,"enrollmentInfo":63,"targetDuration":20,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":20,"overallStatus":29,"whyStopped":20,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Tanta University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Study group","EXPERIMENTAL","Children with refractory nocturnal enuresis or dysfunctional voiding.",[13],"Drug: Botulinium Toxin-A",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Botulinium Toxin-A","Patients will be injected with botulinium toxin-A",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Ahmad M Shalaby, MBBCH","CONTACT","00201021847979","Ahmed.m.shalaby97@gmail.com",[28],{"facility":5,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"RECRUITING","Tanta","El-Gharbia","31527","Egypt","EG",{"type":36,"coordinates":37},"Point",[38,39],31.00192,30.78847,{"lat":39,"lon":38},[42,43,46,48],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"name":44,"role":45,"phone":20,"phoneExt":20,"email":20},"Osama M ElGamal, MD","SUB_INVESTIGATOR",{"name":47,"role":45,"phone":20,"phoneExt":20,"email":20},"Mohamed A Omar, MD",{"name":49,"role":45,"phone":20,"phoneExt":20,"email":20},"Mohamed I Elmaadawy, MD",{"type":51,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Ahmad Mohamed Elsaied Shalaby","Resident of Urology, Tanta University, Tanta, Egypt","100633191","local-injection-of-botulinium-toxin-a-in-children-with-dysfunctional-voiding-or-refractory-nocturnal-eneuresis-100633191",false,"NCT07523477","Local Injection of Botulinium Toxin-A in Children With Dysfunctional Voiding or Refractory Nocturnal Eneuresis","Evaluation of Local Injection of Botulinium Toxin-A in Children With Dysfunctional Voiding or Refractory Nocturnal Eneuresis","Inclusion Criteria:\n\n* Children \\\u003C 18 years.\n* Both sexes.\n* Patients with refractory nocturnal enuresis or dysfunctional voiding who are not responding to the traditional treatment.\n\nExclusion Criteria:\n\n* Bleeding disorders.\n* Neuromusclar disorder(e.g.,Myasthenia gravis).\n* Patients who are not fit for anaesthesia.\n* Active urinary tract infection (UTI).","ALL","18 Years",{"count":64,"type":65},64,"ESTIMATED","INTERVENTIONAL",[68],"NA","The aim of this study is to evaluate the outcome of botulinum toxin A (BTX-A) injection for management of children with :\n\nA-Dysfunctional voiding who are not responding to traditional treatment. B-Refractory nocturnal enuresis.",[71,17,72,73,74],"Local Injection","Children","Dysfunctional Voiding","Refractory Nocturnal Eneuresis","2026-04-05",{"date":77,"type":78},"2026-04-13","ACTUAL",{"date":80,"type":78},"2025-06-01",{"date":82,"type":65},"2026-12-01",{"name":5,"class":6},1]